The effect of individualized diet challenges consisting of allergenic foods on TNF-α and IL-1β levels in patients with rheumatoid arthritis

Rheumatology

Volumn 43, Issue 11, 2004, Pages 1429-1433

  Karatay, S ^a   Erdem, T ^a   Yildirim, K ^a   Melikoglu, M A ^a   Ugur, M ^a   Cakir, E ^a   Akcay, F ^a   Senel, K ^a  

^a ATATURK UNIVERSITY   (Turkey)

Author keywords

Cytokines; Diet therapy; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; FOOD ALLERGEN; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL OBSERVATION; CONTROLLED STUDY; CORN; DIET RESTRICTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOOD ALLERGY; HUMAN; JOINT STIFFNESS; MALE; MEDICAL ASSESSMENT; PAIN ASSESSMENT; PATIENT SELECTION; PRICK TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROVOCATION TEST; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; RICE; STATISTICAL SIGNIFICANCE;

ADULT; ALLERGENS; ARTHRITIS, RHEUMATOID; DIET; FEMALE; FOOD HYPERSENSITIVITY; HUMANS; INTERLEUKIN-1; MALE; MIDDLE AGED; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; SKIN TESTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 8344255769     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh366     Document Type: Article

References (32)

1. Sicherer SH. Manifestations of food allergy: evaluation and management. Am Fam Physician 1999;59:415-24.
2. Sicherer SH. Food allergy: when and how to perform oral food challenges. Pediatr Allergy Immunol 1999;10:226-34.
3. Kaufman W. Food-induced, allergic musculoskeletal syndromes. Ann Allergy 1953;11:179-84.
4. Gaby AR. The role of hidden food allergy/intolerance in chronic disease. Altern Med Rev 1998;3:90-100.
5. Darlington LG, Ramsey NW, Mansfield JR. Placebo-controlled, blind study of dietary manipulation therapy in rheumatoid arthritis. Lancet 1986;1:236-8.
6. van de Laar MA, van der Korst JK. Food intolerance in rheumatoid arthritis. A double blind, controlled trial of the clinical effects of elimination of milk allergens and azo dyes. Ann Rheum Dis 1992;51: 298-302.
7. Taylor PC. Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. Curr Pharm Des 2003;9:1095-106.
8. Dayer JM. Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis? J Rheumatol Suppl 2002;65:10-5.
9. Grimble RF, Howell WM, O'Reilly G et al. The ability of fish oil to suppress tumor necrosis factor alpha production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor alpha production. Am J Clin Nutr 2002;76:454-9.
10. Darlington LG, Stone TW. Antioxidants and fatty acids in the amelioration of rheumatoid arthritis and related disorders. Br J Nutr 2001;85:251-69.
11. Endres S, Ghorbani R, Kelley VE et al. The effects of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265-71.
12. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
13. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
14. Darlington LG, Ramsey NW. Review of dietary therapy for rheumatoid arthritis. Br J Rheumatol 1993;32:507-14.
15. Fries JF, Spitz P, Kraines RG. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
16. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakas TG, Grieveson P. Clinical studies with an articular index for the assessments of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;147:768-9.
17. Skoldstam L, Magnusson KE. Fasting, intestinal permeability, and rheumatoid arthritis. Rheum Dis Clin North Am 1991;17:363-71.
18. Richardson C, Emery P. Laboratory markers of disease activity. J Rheumatol Suppl 1996;44:23-30.
19. Pike MC, Synderman R. Structure and function of monocytes and macrophages. In: McCarty DJ, Kopman WJ, eds. Arthritis and allied conditions. London, 1993:347-76.
20. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
21. Borish L, Mascali JJ, Rosenwasser LJ. IgE-dependent cytokine production by human peripheral blood mononuclear phagocytes. J Immunol 1991;146:63-7.
22. Tetlow LC, Woolley DE. Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies. Ann Rheum Dis 1995;54:896-903.
23. Woolley DE, Tetlow LC. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res 2000;2:65-74.
24. Emery P, Buch M. The aetiology and pathogenesis of rheumatoid arthritis. Hosp Pharmacist 2002;9:5-9.
25. Reich K, Westphal G, Konig IR et al. Cytokine gene polymorphisms in atopic dermatitis. Br J Dermatol 2003;148:1237-41.
26. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002;4(Suppl. 3):S265-72.
27. Fugger L, Svejgaard A. Association of MHC and rheumatoid arthritis: HLA-DR4 and rheumatoid arthritis-studies in mice and men. Arthritis Res 2000;2:208-11.
28. Aron Y, Desmazes-Dufeu N, Matran R et al. Evidence of a strong, positive association between atopy and the HLA classII alleles DR4 and DR7. Clin Exp Allergy 1996;26:821-8.
29. Howell WM, Turner SJ, Hourihane JO, Dean TP, Warner JO. HLA class II DRB1, DQB1 and DPB1 genotypic associations with peanut allergy: evidence from a family-based and case-control study. Clin Exp Allergy 1998;28:156-62.
30. Mansur AH, Williams GA, Bishop DT et al. Evidence for a role of HLA DRB1 alleles in the control of IgE levels, strengthened by interacting TCR A/D marker alleles. Clin Exp Allergy 2000;30: 1371-8.
31. Young RP, Dekker JW, Wordsworth BP et al. HLA-DR and HLA-DP genotypes and immunoglobulin E responses to common major allergens. Clin Exp Allergy 1994;24:431-9.
32. Zwerina J, Hayer S, Tohidast-Akrad M et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50:277-90.